X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bibw 2992 (107) 107
oncology (100) 100
index medicus (96) 96
humans (88) 88
afatinib (84) 84
open-label (50) 50
female (45) 45
egfr (44) 44
gefitinib (44) 44
quinazolines - therapeutic use (40) 40
acquired-resistance (39) 39
cell lung-cancer (38) 38
cancer (36) 36
erbb family blocker (36) 36
pharmacology & pharmacy (36) 36
tyrosine kinase inhibitor (35) 35
lung neoplasms - drug therapy (34) 34
middle aged (34) 34
chemotherapy (33) 33
growth-factor receptor (32) 32
receptor, epidermal growth factor - antagonists & inhibitors (32) 32
1st-line treatment (31) 31
carcinoma, non-small-cell lung - drug therapy (31) 31
erlotinib (31) 31
male (31) 31
afatinib bibw 2992 (30) 30
aged (30) 30
protein kinase inhibitors - therapeutic use (29) 29
adult (28) 28
mutation (27) 27
quinazolines - adverse effects (27) 27
care and treatment (26) 26
epidermal growth factor (26) 26
lung cancer, non-small cell (26) 26
antineoplastic agents - therapeutic use (25) 25
egfr mutations (25) 25
quinazolines - administration & dosage (25) 25
adenocarcinoma (24) 24
lung cancer (24) 24
medicine & public health (24) 24
research (23) 23
tyrosine kinase inhibitors (23) 23
non-small cell lung cancer (21) 21
pharmacokinetics (21) 21
phase-i (21) 21
trial (21) 21
tumors (21) 21
epidermal growth factor receptor (20) 20
neoplasms - drug therapy (20) 20
phase-ii trial (20) 20
quinazolines - pharmacokinetics (20) 20
receptor, erbb-2 - antagonists & inhibitors (20) 20
animals (19) 19
tyrosine kinase (19) 19
treatment outcome (18) 18
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
lung neoplasms - genetics (17) 17
pharmacology/toxicology (17) 17
quinazolines - pharmacology (17) 17
tyrosine (17) 17
hematology, oncology and palliative medicine (16) 16
inhibitor (16) 16
protein kinase inhibitors - pharmacology (16) 16
aged, 80 and over (15) 15
antineoplastic agents - pharmacology (15) 15
breast cancer (15) 15
carcinoma, non-small-cell lung - genetics (15) 15
drug therapy (15) 15
health aspects (15) 15
receptor, epidermal growth factor - genetics (15) 15
antimitotic agents (14) 14
antineoplastic agents (14) 14
lung-cancer (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
cancer research (13) 13
lung neoplasms - pathology (13) 13
maximum tolerated dose (13) 13
mutations (13) 13
nsclc (13) 13
phase i (13) 13
receptor, epidermal growth factor - metabolism (13) 13
receptor, erbb-2 - metabolism (13) 13
resistance (13) 13
solid tumors (13) 13
analysis (12) 12
breast neoplasms - drug therapy (12) 12
carcinoma, non-small-cell lung - pathology (12) 12
her2 (12) 12
i dose-escalation (12) 12
kinases (12) 12
metastasis (12) 12
previously treated patients (12) 12
protein kinase inhibitors - adverse effects (12) 12
advanced solid tumors (11) 11
dose-response relationship, drug (11) 11
drug resistance, neoplasm (11) 11
egf receptor (11) 11
neoplasms (11) 11
pharmacology (11) 11
respiratory tract diseases (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Revue de Pneumologie Clinique, ISSN 0761-8417, 10/2014, Volume 70, Issue 5, pp. 279 - 285
Afatinib (BIBW 2992) is an irreversible multi-target HER receptor tyrosine kinase inhibitor developed in patients with advanced solid tumours. Several phase I... 
BIBW 2992 | Afatinib | Tyrosine kinase inhibitor | Lung cancer | EGFR
Journal Article
Revue de Pneumologie clinique, ISSN 0761-8417, 10/2014, Volume 70, Issue 5, pp. 279 - 285
L’afatinib (BIBW 2992) est un inhibiteur de tyrosine kinase de nouvelle génération, irréversible et multicible (ciblant plusieurs récepteurs de la famille... 
Inhibiteur tyrosine kinase | BIBW 2992 | Afatinib | Tyrosine kinase inhibitor | Lung cancer | Cancer bronchique | EGFR
Journal Article
British Jounal of Cancer, ISSN 0007-0920, 01/2008, Volume 98, Issue 1, pp. 80 - 85
To assess tolerability, pharmacokinetics ( PK), pharmacodynamics ( PD) and clinical activity of the dual epidermal growth factor receptor ( EGFR) 1 and 2 (... 
BIBW 2992 | PROTEIN | SAFETY | epidermal growth factor receptor | pharmacokinetics | MALIGNANCIES | phase I | tyrosine kinase inhibitor | CANCER | UMCG Approved | ONCOLOGY
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2012, Volume 69, Issue 4, pp. 891 - 899
This Phase I study determined the maximum-tolerated dose (MTD) of afatinib (Afatinib is an investigational compound and its safety and efficacy have not yet... 
BIBW 2992 | Phase I | Medicine & Public Health | Afatinib | Tyrosine kinase inhibitor | Non-small cell lung cancer | Cancer Research | Oncology | Pharmacology/Toxicology | Epidermal growth factor receptor | GEFITINIB | TYROSINE KINASE | EGFR | TRIAL | ONCOLOGY | EGFR/HER2 INHIBITOR | PHARMACOLOGY & PHARMACY | MUTATIONS | RECEPTORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Lung Neoplasms - enzymology | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Tyrosine | Medical research | Medical colleges | Care and treatment | Lung cancer | Oncology, Experimental | Research | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Complications and side effects | Chemotherapy | Enzyme inhibitors | Epidermal growth factor | Erlotinib | Analysis | Medicine, Experimental | Skin | Gefitinib | Tumors | Cancer | Index Medicus
Journal Article
Journal Article
Future Oncology, ISSN 1479-6694, 07/2011, Volume 7, Issue 7, pp. 817 - 825
Afatinib (BIBW 2992), a novel aniline-quinazoline derivative, irreversibly and equipotently targets the intrinsic kinase activity of all active ErbB receptor... 
afatinib | BIBW 2992 | EGFR/HER2 | TKI | NSCLC | GEFITINIB | TYROSINE KINASE | FAILURE | EGFR | TRIAL | THERAPY | ONCOLOGY | EGFR/HER2 INHIBITOR | HER2 | IRREVERSIBLE INHIBITOR
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2013, Volume 31, Issue 3, pp. 734 - 741
Background A phase I study to assess the maximum tolerated dose (MTD) of a short course of afatinib in combination with docetaxel for the treatment of solid... 
BIBW 2992 | Phase I | Medicine & Public Health | Afatinib | Tyrosine kinase inhibitor | Oncology | Pharmacology/Toxicology | Pharmacokinetics | Epidermal growth factor receptor | GEFITINIB | CARBOPLATIN | KINASE INHIBITOR | BIBW-2992 | LINES | PACLITAXEL | CELL LUNG-CANCER | TRIAL | ONCOLOGY | PHARMACOLOGY & PHARMACY | ERLOTINIB | Skin Diseases - chemically induced | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Male | Antineoplastic Agents - administration & dosage | Neoplasms - drug therapy | Taxoids - pharmacokinetics | Taxoids - administration & dosage | Maximum Tolerated Dose | Neoplasms - blood | Antineoplastic Agents - adverse effects | Quinazolines - adverse effects | Adult | Female | Quinazolines - administration & dosage | Aged | Antineoplastic Agents - pharmacokinetics | Gastrointestinal Diseases - chemically induced | Taxoids - adverse effects | Antimitotic agents | Complications and side effects | Patient outcomes | Dosage and administration | Research | Drug therapy, Combination | Antineoplastic agents | Drug therapy | Tumors | Studies | Medical research | Prescription drugs | Chemotherapy | Statistical analysis | Research & development--R&D | Pharmacology | Cancer therapies | Index Medicus | Phase I Studies
Journal Article
STRAHLENTHERAPIE UND ONKOLOGIE, ISSN 0179-7158, 05/2007, Volume 183, Issue 5, pp. 256 - 264
Journal Article
Strahlentherapie und Onkologie, ISSN 0179-7158, 5/2007, Volume 183, Issue 5, pp. 256 - 264
Journal Article
Journal Article